Analyst Upgrades: LinkedIn, SS&C Tech, Biogen Idec

Analysts upwardly revised their ratings on LinkedIn Corp (LNKD), SS and C Technologies Holdings Inc (SSNC), Biogen Idec Inc (BIIB)

Feb 3, 2015 at 9:15 AM
facebook twitter linkedin


Analysts are weighing in today on professional social network LinkedIn Corp (NYSE:LNKD), financial software services provider SS and C Technologies Holdings Inc (NASDAQ:SSNC), and biopharmaceutical giant Biogen Idec Inc (NASDAQ:BIIB). Here's a quick roundup of today's bullish brokerage notes on LNKD, SSNC, and BIIB.

  • LNKD is up 2.4% in electronic trading, thanks to a pair of price-target hikes. Specifically, Goldman Sachs raised its target price by $30 to $280 and added the equity to its "conviction buy" list. Also boosting its price target on LNKD was J.P. Morgan Securities, which lifted its expected price to $253 from $244 and kept its "overweight" rating. So far in 2015, the stock has dropped 2.2% to finish yesterday at $224.57, but most analysts remain in the bulls' corner. Of the 27 brokerage formers following LinkedIn Corp, 19 rate it a "buy" or better, with eight deeming it a "hold," and no "sells" to be found. LNKD will report fourth-quarter earnings after the close this Thursday.

  • After announcing that it is buying Advent Software, Inc. (NASDAQ:ADVS) for $2.29 billion, SSNC saw its price target hiked by $20 to $70 at J.P. Morgan Securities, and was upgraded to "overweight" from "neutral." From a technical perspective, SS and C Technologies Holdings Inc has been stellar, adding over 44% in the past 52 weeks to end yesterday at $54.55. Options traders have responded by grabbing calls at an alarming rate. SSNC's Schaeffer's put/call open interest ratio (SOIR) of 0.04 is at an annual low, meaning short-term speculators have been far more call-skewed of late than normal. Ahead of the bell, SSNC is pointed 5% higher.

  • BIIB has been on a roll in 2015, adding nearly 15%, thanks in no small part to last week's earnings-induced bull gap. BIIB closed yesterday at $390, and is pointed 0.2% higher in pre-market trading, after Leerink boosted its price target to $475 -- territory never before charted -- from $399, while maintaining its "outperform" rating. Still, short-term options traders have preferred puts over calls, as Biogen Idec Inc's SOIR of 1.34 is at an annual high.

Grab your FREE Eternal Contrarian report!


 




 
Special Offers from Schaeffer's Trading Partners